AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mitral regurgitation in CHF
Number of subjects: 1321
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sP-sel concentrations
Number of subjects: 1321
Study 12509359 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech recognition technology
Number of subjects: 2
Study 12509359 — intervention group
Group type: COMPARATOR
Intervention: Standard transcription
Number of subjects: 2
Study 10378172 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing longhand about a stressful experience
Number of subjects: 80
Study 10378172 — intervention group
Group type: COMPARATOR
Intervention: Typing about a stressful experience
Number of subjects: 80
Study 10378172 — intervention group
Group type: COMPARATOR
Intervention: Writing longhand about a neutral topic
Number of subjects: 80
Study 10378172 — intervention group
Group type: COMPARATOR
Intervention: Typing about a neutral topic
Number of subjects: 80
Study 8694168 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1 mg
Number of subjects: 120
Study 8694168 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.5 mg
Number of subjects: 120
Study 8694168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 120
Study 1654183 — intervention group
Group type: COMPARATOR
Intervention: Vitamins B6 & B12
Number of subjects: 61
Study 1654183 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 61
Study 1654183 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand splint
Number of subjects: 61
Study 1654183 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint combined with vitamins
Number of subjects: 61
Study 1654183 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint combined with injection
Number of subjects: 61
Study 6671816 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (10 weeks, regular attendance, daily practice for white elders)
Number of subjects: 106
Study 6671816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study 31141429 — intervention group
Group type: EXPERIMENTAL
Intervention: RC (2500 Hz, burst 100 Hz, phase duration 200 μs)
Number of subjects: 27
Study 31141429 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (100 Hz, phase duration 200 μs)
Number of subjects: 27
Study 31141429 — intervention group
Group type: EXPERIMENTAL
Intervention: RC
Number of subjects: 27
Study 31141429 — intervention group
Group type: EXPERIMENTAL
Intervention: PC
Number of subjects: 27
Study 31141429 — intervention group
Group type: COMPARATOR
Intervention: RC and PC
Number of subjects: 27
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of isoleucine, lysine, tyrosine, alanine, threonine, methionine, valine, histidine, aspartic acid, and branched chain, alkaline, and alcoholic amino acids
Number of subjects: 3881
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan, glutamic acid, and acidic amino acids
Number of subjects: 3881
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine
Number of subjects: 3881
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 3881
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine, alanine, methionine, aspartic acid, and alkaline amino acids
Number of subjects: 3881
Study 31235103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan and glutamic acid
Number of subjects: 3881
Study 28771671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored vitamin K dosing regimen (based on index INR and body surface area)
Number of subjects: 181
Study 28771671 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose vitamin K regimen (1 or 2 mg)
Number of subjects: 181
Study 28771671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored vitamin K dosing regimen
Number of subjects: 181
Study 28771671 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose vitamin K regimen
Number of subjects: 181
Study 26249766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysinate (Algidrin® Pediátrico, FARDI S.A.)
Number of subjects: 24
Study 26249766 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen base (Dalsy®, Abbott Laboratories S.A.)
Number of subjects: 24
Study 23816477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 10151
Study 23816477 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10151
Study 22403978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nHAP dentifrice
Number of subjects: 30
Study 22403978 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% nHAP dentifrice
Number of subjects: 30
Study 22403978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm fluoride dentifrice
Number of subjects: 30
Study 22403978 — intervention group
Group type: COMPARATOR
Intervention: 10% nHAP dentifrice (control for healthy block)
Number of subjects: 30
Study 19947259 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 90
Study 19947259 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (Ibuprofen sustained release capsule)
Number of subjects: 90
Study 19947259 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (no treatment)
Number of subjects: 90
Study 17391568 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-isomer-rich tomato sauce (26.4 mg total lycopene/100 g sauce; 45 % cis-isomers)
Number of subjects: 12
Study 17391568 — intervention group
Group type: COMPARATOR
Intervention: all-trans-rich tomato sauce (32.5 mg total lycopene/100 g sauce; 5 % cis-isomers)
Number of subjects: 12
Study 12504655 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Response (CR)
Number of subjects: 341
Study 12504655 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Response (PR)
Number of subjects: 341
Study 12504655 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable Disease (SD)
Number of subjects: 341
Study 12504655 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Disease (PD)
Number of subjects: 341
Study 10977106 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg, alternate days)
Number of subjects: 22071
Study 9069587 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 890
Study 9069587 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHA)
Number of subjects: 890
Study 9069587 — intervention group
Group type: COMPARATOR
Intervention: OHA
Number of subjects: 890
Study 8444822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg daily of oral zinc sulphate for 6 weeks)
Number of subjects: 26
Study 8444822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 26
Study 8444822 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet introduction
Number of subjects: 26
Study 3538262 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in one stage of the trial
Number of subjects: 741
Study 3538262 — intervention group
Group type: COMPARATOR
Intervention: Control treatment in adjacent stage
Number of subjects: 741
Study 28714343 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management and Exercise Group
Number of subjects: 80
Study 28714343 — intervention group
Group type: COMPARATOR
Intervention: Educational Group
Number of subjects: 80
Study 26948484 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified assertive community treatment
Number of subjects: 521
Study 26948484 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment at community mental health centres
Number of subjects: 521
Study 26948484 — intervention group
Group type: COMPARATOR
Intervention: Frequent-stable trajectory
Number of subjects: 521
Study 26948484 — intervention group
Group type: COMPARATOR
Intervention: Frequent-increasing trajectory
Number of subjects: 521
Study 26948484 — intervention group
Group type: EXPERIMENTAL
Intervention: All trajectories
Number of subjects: 521
Study 25491618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (2 mcg/kg)
Number of subjects: 100
Study 25491618 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl (40-70 mcg/kg)
Number of subjects: 100
Study 21678181 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 87
Study 21678181 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 87
Study 20070633 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention (PALSA)
Number of subjects: 1999
Study 18375321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 microg/kg/min of HANP (LH)
Number of subjects: 45
Study 18375321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microg/kg/min of HANP (HH)
Number of subjects: 45
Study 18375321 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (SA)
Number of subjects: 45
Study 15701910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily
Number of subjects: 3922
Study 15701910 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose aiming for INR 2.0 to 3.0)
Number of subjects: 3922
Study 15701910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3922
Study 15701910 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3922
Study 15701910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran and Warfarin
Number of subjects: 3922
Study 12787855 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 182
Study 12787855 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 182
Study 12787855 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics (CA)
Number of subjects: 182
Study 10658044 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (3.28 +/- 0.21 liters)
Number of subjects: 8
Study 10658044 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + Carbohydrate (3.39 +/- 0.23 liters of solution containing 204 +/- 14 g of carbohydrate)
Number of subjects: 8
Study 10658044 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (204 +/- 14 g in 0.49 +/- 0.03 liter of solution)
Number of subjects: 8
Study 10658044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.37 +/- 0.02 liter of water with no carbohydrate)
Number of subjects: 8
Study 8647574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1891
Study 1831248 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusions of sufentanil citrate
Number of subjects: 7
Study 1831248 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusions of morphine in 0.5% bupivacaine (MS-MARC)
Number of subjects: 7
Study 1831248 — intervention group
Group type: COMPARATOR
Intervention: Switching from initial sufentanil citrate infusions to MS-MARC
Number of subjects: 7
Study 7117680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol and hyoscine
Number of subjects: 101
Study 7117680 — intervention group
Group type: COMPARATOR
Intervention: Omnopon and hyoscine
Number of subjects: 101
Study 30776650 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg
Number of subjects: 20
Study 30776650 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 μg
Number of subjects: 20
Study 30776650 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 1000 μg
Number of subjects: 20
Study 30776650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30066604 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support interventions targeting family members
Number of subjects: 20
Study 30066604 — intervention group
Group type: COMPARATOR
Intervention: Control actions by family members
Number of subjects: 20
Study 26655562 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face nursing interventions
Number of subjects: 104
Study 26655562 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrance interview
Number of subjects: 104
Study 26655562 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model of predictors
Number of subjects: 104
Study 26655562 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrance interview (strongest predictor)
Number of subjects: 104
Study 25532088 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 60
Study 25532088 — intervention group
Group type: COMPARATOR
Intervention: Fascia iliaca compartment block (FIC)
Number of subjects: 60
Study 22247360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with conventional combination therapy for 24 months
Number of subjects: 378
Study 22247360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified remission score based on age, sex, and tender joint count (TJC)
Number of subjects: 378
Study 19201183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-fortified fermented milk (high content, 16 mg lutein)
Number of subjects: 24
Study 19201183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-fortified fermented milk (low content, 8 mg lutein)
Number of subjects: 24
Study 19201183 — intervention group
Group type: COMPARATOR
Intervention: In vitro assessment of lutein ester hydrolysis
Number of subjects: 24
Study 17391579 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal multifaceted sedation course (4-hour duration)
Number of subjects: 48
Study 17391579 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning (no formal teaching)
Number of subjects: 48
Study 16326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate, 2 g/70 kg, infused intravenously during and for 3 days postoperatively
Number of subjects: 150
Study 16326293 — intervention group
Group type: COMPARATOR
Intervention: Codeine, 60 mg/70 kg, given orally 4 times a day for 3 days
Number of subjects: 150
Study 16326293 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium, 75 mg, given orally twice a day for 3 days
Number of subjects: 150
Study 11983638 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group dynamic psychotherapy (BGDP)
Number of subjects: 83
Study 11983638 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (control)
Number of subjects: 83
Study 11983638 — intervention group
Group type: EXPERIMENTAL
Intervention: BGDP
Number of subjects: 83
Study 9617980 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg twice a day)
Number of subjects: 37
Study 9617980 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5-75 mg twice a day)
Number of subjects: 37
Study 9617980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (10-20 mg three times a day)
Number of subjects: 37
Study 9617980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7696059 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 20
Study 7696059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 MAC of end‐tidal isoflurane
Number of subjects: 20
Study 7696059 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia alone
Number of subjects: 20
Study 7696059 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia with isoflurane
Number of subjects: 20
Study 7696059 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia with domperidone
Number of subjects: 20
Study 7696059 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia with isoflurane and domperidone
Number of subjects: 20
Study 1978500 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (150-600 mg/day)
Number of subjects: 9
Study 1978500 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-45 mg/day)
Number of subjects: 9
Study 1978500 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 9
Study 1978500 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 9
Study 7017492 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncaspin suspension (3 tablespoonfuls a day)
Number of subjects: 15
Study 7017492 — intervention group
Group type: COMPARATOR
Intervention: Recognised commercial preparation (3 tablespoonfuls a day)
Number of subjects: 15
Study 31127612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Number of subjects: 92
Study 31127612 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 92
Study 31127612 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-A with more than 3 months follow-up treatment
Number of subjects: 92
Study 27655859 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563
Study 27655859 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study 26126161 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 412
Study 26126161 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 412
Study 25194079 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine plus intermittent percutaneous needle sacral nerve stimulation (IPN‐SNS)
Number of subjects: 240
Study 25194079 — intervention group
Group type: COMPARATOR
Intervention: tolterodine only
Number of subjects: 240
Study 21107287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Vinorelbine
Number of subjects: 616
Study 21107287 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Number of subjects: 616
Study 21107287 — intervention group
Group type: COMPARATOR
Intervention: Younger patient cohort
Number of subjects: 616
Study 21107287 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity parameters
Number of subjects: 616
Study 19844234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy (1500 mg once daily)
Number of subjects: 100
Study 17537071 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint family therapy (CFT)
Number of subjects: 40
Study 17537071 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated family therapy (SFT)
Number of subjects: 40
Study 17537071 — intervention group
Group type: EXPERIMENTAL
Intervention: CFT
Number of subjects: 40
Study 17537071 — intervention group
Group type: EXPERIMENTAL
Intervention: SFT
Number of subjects: 40
Study 17142202 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + HCTZ 12.5 mg
Number of subjects: 130
Study 17142202 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg + HCTZ 12.5 mg
Number of subjects: 130
Study 12661796 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0
Study 12661796 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 10547169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 300
Study 10547169 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 300
Study 8852310 — intervention group
Group type: EXPERIMENTAL
Intervention: Centroid method (study group)
Number of subjects: 10
Study 8852310 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (control group)
Number of subjects: 10
Study 1991894 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 307
Study 1991894 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 307
Study 6346348 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 6
Study 6346348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29777663 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (ENG)
Number of subjects: 2963
Study 29777663 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant (LNG)
Number of subjects: 2963
Study 29777663 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 2963
Study 27110107 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 28
Study 27110107 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 28
Study 25722221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Metformin (850 mg twice daily after meals)
Number of subjects: 37
Study 25722221 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg/day) plus Placebo
Number of subjects: 37
Study 24325472 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-3 PUFA meal (0.97 n-6/n-3 ratio)
Number of subjects: 16
Study 24325472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low n-3 PUFA meal (8.80 n-6/n-3 ratio)
Number of subjects: 16
Study 24325472 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 16
Study 24325472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia group (HTG)
Number of subjects: 16
Study 19949016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise program (n = 29)
Number of subjects: 57
Study 19014306 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatments for depression
Number of subjects: 103
Study 15961289 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructions in addition to verbal instructions
Number of subjects: 0
Study 15961289 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions only (Control)
Number of subjects: 0
Study 12734019 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel approach using randomization distribution to compute anticipated maximum bias
Number of subjects: 0
Study 11284461 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500 mg/day, adjustable after 1-3 days)
Number of subjects: 163
Study 11284461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 8670663 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinotopic mapping strategies using magnetic recordings of brain activity and anatomical MRI
Number of subjects: 0
Study 1931405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal block (T4-S5)
Number of subjects: 21
Study 1931405 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Control)
Number of subjects: 21
Study 1931405 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural block (T4-S5)
Number of subjects: 21